ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 22 Issue : 3
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
Ivabradine, a novel heart rate slower: Is it a sword of double blades in patients with idiopathic dilated cardiomyopathy? [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(5): 402-406 | DOI: 10.5152/akd.2011.110  

Ivabradine, a novel heart rate slower: Is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?

Mona Rayan1, Mazen Tawfik1, Ali Alabd1, Amr Gamal1
Department of Cardiology, Ain Shams University, Cairo-Egypt

Objective: To prospectively assess the safety and efficacy of ivabradine in patients with idiopathic dilated cardiomyopathy. Methods: We included 35 patients with idiopathic dilated cardiomyopathy with an ejection fraction (EF) <40% and heart rate >70 beats/min despite optimal medical therapy, according to the international guidelines in this prospective, non-randomized, single-arm, open-label safety study. Ivabradine was used as an add-on therapy to the maximally tolerated b-blocker in an increasing titrated dose till a target dose of 15 mg/day or resting heart rate of 60 beats/min for 3 months. During follow-up period the safety, patient tolerance and efficacy of this drug were assessed. All patients underwent 12-lead resting electrocardiography and Holter monitoring at inclusion and after 3 months. Statistical analysis was accomplished using paired t-test and Pearson correlation analysis. Results: We found a significant reduction in the resting heart rate by a mean of 25.99.4%, without a significant change of blood pressure. There was no prolongation of PR, QTc or QRS durations. Ventricular ectopic activity showed significant reduction (p<0.001). There was a significant correlation between the resting heart rate, NYHA and left ventricular ejection fraction (p<0.001 for both). One patient developed photopsia and decompensation was observed in another patient. Conclusion: Ivabradine is a safe and effective drug in reducing resting heart rate, improving NYHA functional class without undesirable effects on conduction parameters or ectopic activity.

Keywords: Ivabradine, dilated cardiomyopathy, heart failure, safety, efficacy


Mona Rayan, Mazen Tawfik, Ali Alabd, Amr Gamal. Ivabradine, a novel heart rate slower: Is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?. Anatol J Cardiol. 2011; 11(5): 402-406


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright 2018 Turkish Society of Cardiology